

# Rebecca R. Miles, Ph.D.

---

Pendleton, IN | [milesrr@gmail.com](mailto:milesrr@gmail.com) | 765-617-7708

## Professional Summary

- Passionate and experienced drug discovery scientist motivated to bring breakthrough medicines to patients in need through scientific excellence, innovation, collaboration, authentic leadership and integrity.
- During a 25 year career at Lilly, demonstrated a proven track record of both scientific and organizational leadership to support the development of a wide range of small molecule, peptide, antibody and oligonucleotide discovery efforts in the areas of metabolic disease, dyslipidemia, osteoporosis, kidney disease, oncology, immunology, neurodegeneration, and pain.
- Recognized as a leader and champion of genomic technologies at both Eli Lilly and Corteva Agriscience to drive new platforms and targets for the commercial portfolio; leading to patents issued from both endeavors.
- Built a new team for Lilly Genetic Medicines in a start-up environment.
- Created a healthy team culture with direct reports through open and honest communication, relationship building, and providing candid feedback. Passionate about mentoring direct reports and creating opportunities for visibility and advancement within the organization.

## Skills

- Innovator, champion and communicator for oligonucleotides and genetic medicines
- Planning and execution of regional and international scientific conferences
- Effective communication skills through extensive publications and presentations at national and international conferences
- Continuous learning and ability to acquire knowledge and disseminate complex scientific information in new areas quickly
- Experienced drug discovery scientist through all phases of molecule development
- Multiple therapeutic area expertise
- Adaptable to changing business priorities and rapidly evolving therapeutic modalities
- Able to translate business goals and brand awareness into scientific strategy for improved patient outcomes
- Able to articulate and convey complex scientific ideas across a variety of audiences
- Effective project leadership and time management skills to build robust work plans to achieve maximal results
- Able to align priorities across cross-functional partners in a large pharmaceutical company
- Team building and cross collaboration
- Relationship building, emotional intelligence and people development
- Influencing without authority

## Experience

### Chief Executive Officer | ReINA Consulting LLC | 2024 – present

- Consulting services offered for biotech and pharmaceutical companies in all areas of discovery and pre-clinical development of oligonucleotide therapeutics.

### Senior Director | Eli Lilly Genetic Medicines | 2019 – 2024, Retired 2024

- Founding member of Lilly Genetic Medicines and part of leadership team to build oligonucleotide capabilities. Built a team of 10 in vitro and in vivo biologists to support target ID and validation, oligonucleotide sequence selection, chemistry optimization as well as hepatic and extrahepatic delivery platforms.
- Managed and prioritized more than 80 cross-functional projects with multiple therapeutic areas, ADME and chemistry to deliver preclinical assets for diabetes, obesity, hypertriglyceridemia, neurodegeneration, pain, and

immunology. Subject matter expert to establish in vitro and in vivo screening strategies with therapeutic area scientists.

- Experienced team player and effective communicator to build healthy and trusting relationships to help large teams drive oligonucleotide programs through IND enabling studies with aggressive timelines.
- Provide training and coaching in RNAi methods across the company.
- Experience in search and evaluation of external emerging technologies, serving as a subject matter expert in RNA therapeutics for senior leadership.
- Coordinated and managed several CRO relationships to accelerate internal research programs.
- Active coach and mentor to early career professionals.
- Discovery Insights Personality Profiling and Situational Leadership training.

#### **Board of Directors and President-Elect | Oligonucleotide Therapeutic Society | 2021-2024**

- Provide key leadership to board of directors to drive society goals and initiatives.
- Active board member engaged with other leaders in the oligonucleotide field to advance learning and accelerate the advancement of therapeutics.
- Chair of OTS website development committee.
- Chair of sponsorship committee and member of planning committee for 2023 and 2024 annual OTS meeting.
- Member of mentoring program and actively mentoring 2 Ph.D. candidates

#### **Chair and Scientific Advisor | Midwest Symposium on Oligonucleotide Therapeutics | 2022 and 2023**

- Conceptualized and organized a 2 day meeting to bring together more than 150 students and investigators in the Midwestern states to connect and share current oligonucleotide research through posters and presentations.

#### **Senior Principal Biologist | Lilly Research Labs | 1994 to 2009, 2011 to 2019**

- Deep technical expertise in early drug discovery research areas leveraging functional genomics, RNAi and CRISPR screening to support target identification and validation of molecular mechanisms for a wide variety of therapeutic indications including neurodegeneration, peripheral pain, insulin secretion, atherosclerosis, metabolic and lipid disorders, obesity, lung fibrosis, bone formation, osteoporosis, breast cancer, osteoarthritis, kidney disease and wound healing.
- Highly experienced in assay design, development, and validation to support screening of small molecule, peptide, oligonucleotide, and antibody therapeutics for portfolio entry.
- Highly experienced cell biologist that has leveraged primary cells, induced pluripotent cells (iPSC), co-culture systems and AAV expression systems to build platforms for target validation, molecule screening and development.
- Investigation of synthetic mRNA as a novel therapeutic modality. Experience in mRNA synthesis and nanoparticle formulation for in vivo delivery and expression.

#### **Corteva Agriscience | Advanced Technology and Development | 2009-2011**

- Project leader role supporting the development of novel gene editing strategies using zinc-finger nuclease technology in maize to accelerate timelines for trait development. Additionally, provided active research support as a molecular biologist in charge of designing and assembling novel gene targeting vectors for multiple projects. Member of Construct Oversight Committee and Competitive Intelligence Committee.

## Research Assistant | University of Chicago, Chicago, IL

- Investigated the role of estrogen and progesterone receptors in breast cancer.

## Education

### Indiana University School of Medicine | Indianapolis, IN

- Doctor of Philosophy
- Biochemistry and Molecular Biology

### College Of William and Mary | Williamsburg, VA

- Master of Arts
- Biology

### Harvard University | Cambridge, MA

- Visiting Undergraduate
- Biology and Political Science

### Indiana Wesleyan University | Marion, IN

- Bachelors of Science
- Pre-medicine and Political Science

## Membership in Professional Societies

- The Oligonucleotide Therapeutic Society
- RNA Society
- Society for Investigative Dermatology
- Medical Science Liaison Society

## Academic Appointments

- **Visiting Assistant Professor of Biology**, Taylor University, Upland IN Instructor for Cell and Molecular Biology and Introductory Biology
- **Adjunct Faculty**, Indiana Wesleyan University, Marion, IN Instructor for Human Anatomy and Physiology.
- **Teaching Assistant**, College of William and Mary, Williamsburg, VA Introduction to Cell, Molecular and Developmental Biology; Introduction to Organisms, Ecology and Evolution; and Developmental Biology.

## Patents

- **WO2024123646A2 Modified oligonucleotides**. Jibo Wang, Rebecca Ruth Miles, Lacie Marie Chauvigne-Hines, Suntara Cayha, Isabel C Gonzalez Valcarcel.
- **WO2023177972A1 Sarm1 rna interference agents**, Nicholas Alan Babb, Selene Hernandez Buquer, Gregory Lawrence Lackner, Rebecca Ruth Miles, Douglas Raymond Perkins, Jibo Wang, Yaming Wang, Yea Jin Kaeser-Woo

- **US20230212576A1 Mapt rna interference agents**, Barbara Calamani, Sarah Katharina Fritschi, Rebecca Ruth Miles, Peter McCarthy, Douglas Raymond Perkins, Keith Geoffrey Phillips, Kaushambi Roy, Isabel Cristina Gonzalez Valcarcel, Jibo Wang, Shih-Ying Wu, Jeremy S. York
- **WO2022271808A1, Novel rna therapeutics and uses thereof**, Rebecca Ruth Miles, Jibo Wang, Melissa Ann Bellingier, Thomas Patrick Beyer, Christine Chih-Tao Cheng, MariJean Eggen, Gregory Lawrence Lackner
- **US8802921 B2, CA2787594C, AU 2015210438 B2**: Engineered landing pads for gene targeting in plants. William M. Ainley, Ryan C. Blue, Michael G. Murray, David Corbin, Rebecca R. Miles, Steven R. Webb
- **WO2001023562A9**: Osteoprotegerin Regulatory Region. Chandrasekhar S, Halladay DL, Martin TJ, Miles R, Onyia JE, and Thirunavukkarasu K.

## Awards

- **Lilly Endocrine Award for Leadership**
- **Lilly Integrative Biology Elite Award for Teamwork**
- **Lilly Integrative Biology Elite Award for Scientific Achievement**
- **Lilly Innovator Award Top 100**
- **Lilly Research Award Program** – *Transcriptome wide mapping of RNA-protein interactions in liver to dissect the role of post-transcriptional mechanisms in NALFD*, 2-year funding and external collaboration with Dr. Sarath Janga, Indiana University.

## Publications

Deprey K, Batistatou N, Debets MF, Godfrey J, VanderWall KB, **Miles RR**, Shehaj L, Guo J, Andreucci A, Kandasamy P, Lu G, Shimizu M, Vargeese C, Kritzer JA. Quantitative Measurement of Cytosolic and Nuclear Penetration of Oligonucleotide Therapeutics. *ACS Chem Biol*. 2022 Feb 18;17 (2):348-360. doi: 10.1021/acscchembio.1c00830. Epub 2022 Jan 15. PMID: 35034446; PMCID: PMC9252293.

**Miles RR**, Amin PH, Diaz MB, Misra J, Aukerman E, Das A, Ghosh N, Guith T, Knierman MD, Roy S, Spandau DF, Wek RC. The eIF2 kinase GCN2 directs keratinocyte collective cell migration during wound healing via coordination of reactive oxygen species and amino acids. *J Biol Chem*. 2021 Nov;297 (5):101257. doi: 10.1016/j.jbc.2021.101257. Epub 2021 Sep 29. PMID: 34597669; PMCID: PMC8554533.

Borg ML, Massart J, Schönke M, De Castro Barbosa T, Guo L, Wade M, Alsina-Fernandez J, **Miles R**, Ryan A, Bauer S, Coskun T, O'Farrell E, Niemeier EM, Chibalin AV, Krook A, Karlsson HK, Brozinick JT, Zierath JR. Modified UCN2 Peptide Acts as an Insulin Sensitizer in Skeletal Muscle of Obese Mice. *Diabetes*. 2019 Jul;68 (7):1403-1414. doi: 10.2337/db18-1237. Epub 2019 Apr 22. PMID: 31010957.

Ainley WM, Sastry-Dent L, Welter ME, Murray MG, Zeitler B, Amora R, Corbin DR, **Miles RR**, Arnold NL, Strange TL, Simpson MA, Cao Z, Carroll C, Pawelczak KS, Blue R, West K, Rowland LM, Perkins D, Samuel P, Dewes CM, Shen L, Sriram S, Evans SL, Rebar EJ, Zhang L, Gregory PD, Urnov FD, Webb SR, Petolino JF. Trait stacking via targeted genome editing. *Plant Biotechnol J*. 2013 Dec;11 (9):1126-34. doi: 10.1111/pbi.12107. Epub 2013 Aug 19. PMID: 23953646.

**Miles RR**, Perry W, Haas JV, Mosior MK, N'Cho M, Wang JW, Yu P, Calley J, Yue Y, Carter Q, Han B, Foxworthy P, Kowala MC, Ryan TP, Solenberg PJ, Michael LF. Genome-wide screen for modulation of hepatic apolipoprotein A-I (ApoA-I) secretion. *J Biol Chem*. 2013 Mar 1;288 (9):6386-96. doi: 10.1074/jbc.M112.410092. Epub 2013 Jan 15. PMID: 23322769; PMCID: PMC3585073.

Wei T, Kulkarni NH, Zeng QQ, Helvering LM, Lin X, Lawrence F, Hale L, Chambers MG, Lin C, Harvey A, Ma YL, Cain RL, Oskins J, Carozza MA, Edmondson DD, Hu T, **Miles RR**, Ryan TP, Onyia JE, Mitchell PG. Analysis of early changes in the articular cartilage transcriptome in the rat meniscal tear model of osteoarthritis: pathway comparisons with the rat anterior cruciate transection model and with human osteoarthritic cartilage. *Osteoarthritis Cartilage*. 2010 Jul;18(7):992-1000. doi: 10.1016/j.joca.2010.04.012. Epub 2010 Apr 29. PMID: 20434574.

Dotzlaf J, Carpenter J, Luo S, **Miles RR**, Fisher D, Qian YW, Ehsani M, Wang X, Lin A, McClure DB, Chen VJ, Zuckerman SH. Derivation and characterization of monoclonal antibodies against human folypolyglutamate synthetase. *Hybridoma (Larchmt)*. 2007 Jun;26 (3):155-61. doi: 10.1089/hyb.2007.004. PMID: 17600497.

Helvering LM, Adrian MD, Geiser AG, Estrem ST, Wei T, Huang S, Chen P, Dow ER, Calley JN, Dodge JA, Grese TA, Jones SA, Halladay DL, **Miles RR**, Onyia JE, Ma YL, Sato M, Bryant HU. Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus. *Biol Reprod*. 2005 Apr;72 (4):830-41. doi: 10.1095/biolreprod.104.034595. Epub 2004 Dec 1. PMID: 15576828.

Helvering LM, Liu R, Kulkarni NH, Wei T, Chen P, Huang S, Lawrence F, Halladay DL, **Miles RR**, Ambrose EM, Sato M, Ma YL, Frolik CA, Dow ER, Bryant HU, Onyia JE. Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene. *Mol Pharmacol*. 2005 Nov;68 (5):1225-38. doi: 10.1124/mol.105.011478. Epub 2005 Aug 3. PMID: 16079270.

Kulkarni NH, Halladay DL, **Miles RR**, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT, Onyia JE. Effects of parathyroid hormone on Wnt signaling pathway in bone. *J Cell Biochem*. 2005 Aug 15;95(6):1178-90.

Onyia JE, Helvering LM, Gilbert L, Wei T, Huang S, Chen P, Dow ER, Maran A, Zhang M, Lotinun S, Lin X, Halladay DL, **Miles RR**, Kulkarni NH, Ambrose EM, Ma YL, Frolik CA, Sato M, Bryant HU, Turner RT. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. *J Cell Biochem*. 2005 May 15;95 (2):403-18. doi: 10.1002/jcb.20438. PMID: 15779007.

Onyia JE, Galvin RJ, Ma YL, Halladay DL, **Miles RR**, Yang X, Fuson T, Cain RL, Zeng QQ, Chandrasekhar S, Emkey R, Xu Y, Thirunavukkarasu K, Bryant HU, Martin TJ. Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. *J Pharmacol Exp Ther*. 2004 Apr;309(1):369-79. doi: 10.1124/jpet.103.057893. Epub 2004 Jan 12. PMID: 14718597.

Thirunavukkarasu K, Halladay DL, **Miles RR**, Geringer CD, Onyia JE. Analysis of regulator of G-protein signaling-2 (RGS-2) expression and function in osteoblastic cells. *J Cell Biochem*. 2002;85(4):837-50. doi: 10.1002/jcb.10176. PMID: 11968023.

**Miles RR**, Sluka JP, Halladay DL, Santerre RF, Hale LV, Bloem L, Patanjali SR, Galvin RJ, Ma L, Hock

JM, Onyia JE. Parathyroid hormone (hPTH 1-38) stimulates the expression of UBP41, an ubiquitin-specific protease, in bone. *J Cell Biochem.* 2002;85(2):229-42. doi: 10.1002/jcb.10129. PMID: 11948679.

Halladay DL, **Miles RR**, Thirunavukkarasu K, Chandrasekhar S, Martin TJ, Onyia JE. Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. *J Cell Biochem.* 2001;84(1):1-11. doi: 10.1002/jcb.1273. PMID: 11746511.

Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, **Miles RR**, Chandrasekhar S, Martin TJ, Onyia JE. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. *Endocrinology.* 2001 Sep;142(9):4047-54. doi: 10.1210/endo.142.9.8356. PMID: 11517184.

Thirunavukkarasu K, **Miles RR**, Halladay DL, Yang X, Galvin RJ, Chandrasekhar S, Martin TJ, Onyia JE. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. *J Biol Chem.* 2001 Sep 28;276(39):36241-50. doi: 10.1074/jbc.M104319200. Epub 2001 Jul 12. PMID: 11451955.

**Miles RR**, Sluka JP, Halladay DL, Santerre RF, Hale LV, Bloem L, Thirunavukkarasu K, Galvin RJ, Hock JM, Onyia JE. ADAMTS-1: A cellular disintegrin and metalloprotease with thrombospondin motifs is a target for parathyroid hormone in bone. *Endocrinology.* 2000 Dec;141(12):4533-42. doi: 10.1210/endo.141.12.7817. PMID: 11108265.

Thirunavukkarasu K, Halladay DL, **Miles RR**, Yang X, Galvin RJ, Chandrasekhar S, Martin TJ, Onyia JE. The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. *J Biol Chem.* 2000 Aug 18;275(33):25163-72. doi: 10.1074/jbc.M000322200. PMID: 10833509.

Onyia JE, **Miles RR**, Yang X, Halladay DL, Hale J, Glasebrook A, McClure D, Seno G, Churgay L, Chandrasekhar S, Martin TJ. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. *J Bone Miner Res.* 2000 May;15(5):863-71. doi: 10.1359/jbmr.2000.15.5.863. PMID: 10804015.

Thirunavukkarasu K, **Miles RR**, Halladay DL, Onyia JE. Cryptic enhancer elements in luciferase reporter vectors respond to the osteoblast-specific transcription factor Osf2/Cbfa1. *Biotechniques.* 2000 Mar;28(3):506-10. doi: 10.2144/00283st09. PMID: 10723564.

Feister HA, Onyia JE, **Miles RR**, Yang X, Galvin R, Hock JM, Bidwell JP. The expression of the nuclear matrix proteins NuMA, topoisomerase II-alpha, and -beta in bone and osseous cell culture: regulation by parathyroid hormone. *Bone.* 2000 Mar;26(3):227-34. doi: 10.1016/s8756-3282(99)00269-0. PMID: 10709994.

Boguslawski G, Hale LV, Yu XP, **Miles RR**, Onyia JE, Santerre RF, Chandrasekhar S. Activation of osteocalcin transcription involves interaction of protein kinase A- and protein kinase C-dependent pathways. *J Biol Chem.* 2000 Jan 14;275(2):999-1006. doi: 10.1074/jbc.275.2.999. PMID: 10625638.

**Miles RR**, Sluka JP, Santerre RF, Hale LV, Bloem L, Boguslawski G, Thirunavukkarasu K, Hock JM, Onyia JE. Dynamic regulation of RGS2 in bone: potential new insights into parathyroid hormone

signaling mechanisms. *Endocrinology*. 2000 Jan;141(1):28-36. doi: 10.1210/endo.141.1.7229. PMID: 10614620.

Onyia JE, Hale LV, **Miles RR**, Cain RL, Tu Y, Hulman JF, Hock JM, Santerre RF. Molecular characterization of gene expression changes in ROS 17/2.8 cells cultured in diffusion chambers in vivo. *Calcif Tissue Int*. 1999 Aug;65(2):133-8. doi: 10.1007/s002239900671. PMID: 10430646.

McClelland P, Onyia JE, **Miles RR**, Tu Y, Liang J, Harvey AK, Chandrasekhar S, Hock JM, Bidwell JP. Intermittent administration of parathyroid hormone (1-34) stimulates matrix metalloproteinase-9 (MMP-9) expression in rat long bone. *J Cell Biochem*. 1998 Sep 1;70(3):391-401. PMID: 9706876.

**Miles RR**, Turner CH, Santerre R, Tu Y, McClelland P, Argot J, DeHoff BS, Mundy CW, Rosteck PR Jr, Bidwell J, Sluka JP, Hock J, Onyia JE. Analysis of differential gene expression in rat tibia after an osteogenic stimulus in vivo: mechanical loading regulates osteopontin and myeloperoxidase. *J Cell Biochem*. 1998 Mar 1;68(3):355-65. doi: 10.1002/(sici)1097-4644(19980301)68:3<355::aid-jcb6>3.0.co;2-t. PMID: 9518261.

Saha MS, **Miles RR**, Grainger RM. Dorsal-ventral patterning during neural induction in *Xenopus*: assessment of spinal cord regionalization with xHB9, a marker for the motor neuron region. *Dev Biol*. 1997 Jul 15;187(2):209-23. doi: 10.1006/dbio.1997.8625. PMID: 9242418.

Fuchs-Young R, Howe S, Hale L, **Miles R**, Walker C. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. *Mol Carcinog*. 1996 Nov;17(3):151-9. doi: 10.1002/(SICI)1098-2744(199611)17:3<151::AID-MC7>3.0.CO;2-I. PMID: 8944075..

The Isolation and Characterization of a Novel G-protein-coupled receptor involved in Angiogenesis. Master's Thesis, July 1994.

## Presentations

Genetic ablation or pharmacologic inhibition of the natriuretic peptide clearance receptor NPR-C delays Chronic Kidney Disease progression in mouse models. Bhaskariyoti Sarmah, Courtney Wooden, Hana Baker, Derek Yang, Marikka Elia, Stephanie Truhlar, David Stokell, Rebecca Miles, Rohn Millican, Yiqing Feng, Zhonghua Qi, Josef G Heuer, and Matthew D Breyer. American Society of Nephrology (ASN), Kidney Week 2016 Annual Meeting

Comparative Genomics of 3-5% of mRNA Expressed in Osteoblast-Enriched Femoral Metaphyseal Bone. Miles RR, Sluka JP, Hale LV, Travis K, Tu Y, Bloem L, Boguslawski G, Argot J, Hock JM, Santerre RF and Onyia JE. International Conference on Progress in Bone and Mineral Research in Vienna, Austria. April 1998.

Molecular Characterization of Gene Expression Changes in ROS 17/2.8 Cells Cultured in Diffusion Chamber in vivo. Onyia JE, Hale LV, Miles RR, Cain RL, Tu Y, Hulman JF, Hock JM and Santerre RF. International Conference on Progress in Bone and Mineral Research in Vienna, Austria. April 1998.

Thirunavukkarasu K, Miles RR, Halladay DL, Galvin R, Chandrasekhar S, Martin TJ and Onyia JE. The osteoblast-specific transcription factor OSF2 regulates the expression of osteoclast inhibitory factor OPG: Implications for the potential role of OSF2 in bone resorption. *Platform presentation: 1999 American Society for Bone and Mineral Research Meeting. St. Louis, MS.*

Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A, McClure D, Seno G, Churgay L, Chandrasekhar S, and Martin TJ. In vivo demonstration that parathyroid hormone (hPTH1-38) inhibits the expression of osteoprotegerin (OPG) in bone with the kinetics of an immediate early gene. *Platform presentation: 1999 American Society for Bone and Mineral Research Meeting, St. Louis, MS.*

Thirunavukkarasu K, Halladay DL, Miles RR, Santerre RF, and Onyia JE. Regulator of G-Protein Signaling 2 (RGS2) Down Regulates PTH Signaling in Osteoblasts Via the G<sub>s</sub>-Adenylate Cyclase-Protein Kinase A Pathway. *2000 American Society for Bone and Mineral Research Meeting, Toronto, Ontario, Canada.*

Onyia JE, Ma L, Galbreath E, Zhang Q, Zeng QQ, Cain RL, Hoover J, Miles RR, Halladay RR, Hale LV, Santerre RF, Harvey AK, Chandrasekhar S, Fox N, and Yang DD. ADAMTS-1: A Cellular Disintegrin and Metalloprotease with Thrombospondin Motifs is Essential for Normal Bone Growth and PTH Regulated Bone Metabolism. *2001 American Society for Bone and Mineral Research Meeting, Phoenix, AZ.*

Adams CS, Bemis KG, Bryant HU, Chandrasekhar S, Chen P, Dow E, Frolik CA, Gelbert L, Halladay DL, Huang S, Ma L, Miles RR, Onyia JE, and Sato S. Gene Array Analysis of the Bone Effects of Raloxifene and Alendronate Show that Alendronate Strongly Inhibits the Expression of bone formation marker genes. *2002 American Society for Bone and Mineral Research Meeting, San Antonio TX.*

Chandrasekhar S, Halladay DL, Miles RR, Onyia JE, Galvin RGS, Thirunavukkarasu K, Yang X, and Martin TJ. Regulation of osteoprotegerin (OPG) expression by Cbfa1 and TGF-beta. *Midwest Connective Tissue Workshop 2002, Chicago, IL.*

Galvin RJS, Onyia JE, Ma L, Halladay DL, Miles RR, Yang X, Fuson TR, Cain RL, Zeng QQ, Chandrasekhar S, Emkey R, Xu Y, Thirunavukkarasu K, BryantHU, and Martin TJ. Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption. *2003 American Society for Bone and Mineral Research Meeting, Minneapolis, MN.*

Helvering LM, Onyia JE, Dow E, Wei T, Gelbert L, Adams C, Lawrence F, Bemis KG, Halladay DL, Miles RR, Kulkarni NH, Huang S, Chen P, Chandrasekhar S, Frolik CA, Sato M, Ma L, and Bryant HU. RNA profiling of antiresorptives reveal Alendronate and estrogen decrease bone formation genes while Raloxifene maintains their increase in the ovariectomized rat. *2004 World Congress on Osteoporosis, Rio De Janeiro, Brazil.*

## **Abstracts**

Douglas R. Perkins, Graham D. Williams, Ashley S. Varney-Briskey, Selene Hernandez Buquer, Patrick Antonellis, Andrew C. Adams, Malgorzata Gonciarz, Jibo Wang, Rebecca R. Miles (2021) Identification of SARS-COV2 siRNAs that inhibit viral replication. Oligonucleotide Therapeutic Society Meeting.

Rebecca Miles, Parth Amin, Jagannath Misra, Dan Spandau, Ronald Wek (2020) The Integrated Stress Response Facilitates Cutaneous Wound Healing. Cold Spring Harbor Translation Control Meeting

Rebecca Miles, Parth Amin, Jagannath Misra, Dan Spandau, Ronald Wek The Integrated Stress Response Facilitates Cutaneous Wound Healing Society of Investigative Dermatology Annual Meeting 2019

Rebecca Miles, Parth Amin, Jagannath Misra, Dan Spandau, Ronald Wek The Integrated Stress Response and Cutaneous Wound Healing IU School of Medicine Department of Biochemistry Research Day October 2018

Kulkarni NH, Gelbert L, Zhang M, Bemis KG, Maran A, Lin X, Li Q, Mishra S, Halladay DL, Wei T, Chandrasekhar S, Frolik CA, Sato M, Helvering LM, Turner R, Dow E, Adams C, Lawrence F, Miles RR, Huang S, Chen P, Ma L, Bryant HU, and Onyia JE. Gene expression profile identifies different classes of bone therapies: PTH, Alendronate and SERMs. *European Calcified Tissue Society; European Symposium on Calcified Tissue (ECTS) 2004, Nice, France.*

Kulkarni NH, Halladay DL, Miles RR, Frolik CA, Galvin RJS, Fuson TR, Martin TJ, and Onyia JE. Wnt signaling pathway: A target for PTH action in bone and bone cells. *Plenary Poster: 2003 American Society for Bone and Mineral Research Meeting, Minneapolis, MN.*

Thirunavukarsau K, Miles RR, Halladay DL, Yang X, Galvin RJS, Chandrasekhar S, Martin TJ, and Onyia JE. Cbfa- and Smad-binding Elements Mediate TGF $\beta$  Stimulation of Osteoprotegerin (OPG) Gene Expression. *2001 American Society for Bone and Mineral Research Meeting, Phoenix, AZ.*

Halladay DL, Miles RR, Thirunavukarsau K, Chandrasekhar S, Martin TJ and Onyia JE. Identification of Signal Transduction Pathways and Promoter Sequences that Mediate Parathyroid Hormone 1-38 Inhibition of Osteoprotegerin Gene Expression. *2000 American Society for Bone and Mineral Research Meeting, Toronto, Ontario, Canada.*

Parathyroid Hormone Regulates the Expression of NuMA and Topoisomerase II-a in Bone. Feister HA, Yang X, Onyia JE, Miles RR, Hock JM, Bidwell J. *American Society for Bone and Mineral Research (ASBMR), 1998*

Analysis of Differential Gene Expression after an Osteogenic Stimulus in vivo: Mechanical Loading Regulates Osteopontin and Myeloperoxidase. R. Miles, C.H. Turner, R.H. Santerre, Y. Tu, P. McClelland, J. Argot, J.M. Hock, J. Onyia *ASBMR 1997*

Raloxifene, a Selective Estrogen Receptor Modulator, Inhibits Estrogen Stimulated Proliferation of Leiomyoma Cells in Culture. Hale L., Miles R. Howe S., Walker C., Fuchs-Young R. *Society for Gynecological Investigation, 1996.*

Modulation of Fibroid Cells by Steroids and Their Antagonists. Fuchs-Young R., Hale L., Howe S., Miles R. Walker, C. *Barton Creek Symposium, 1995.*

Raloxifene Analogue LY139478 Up-regulates the B form of the Progesterone Receptor in Porcine Bone Marrow-derived Stromal Cells but not Osteoblast-like cells. R. Galvin, R. Miles, P. Bryan, R. Fuchs-Young. *ASBMR 1995.*

Vertebrate Brain Development in *Xenopus*. M. Saha, K. Joubin, R. Miles, C. Sinor. *International Xenopus Conference, June 1994.*

Regulation of the 5' Flanking Region of the Progesterone Receptor Gene by Estrogen and Progesterone Receptors. R. Fuchs-Young, A. Betuzzi, M. Radigan, R. Miles, G. Greene. *National Endocrine Society Meeting, 1992.*

